Loading organizations...
§ Private Profile · Waltham, MA, USA
biopharmaceutical company developing extracellular protein degraders (ATACs) for targeted protein degradation and novel therapeutics.
Avilar Therapeutics is a Waltham, Massachusetts-based biopharmaceutical company that develops extracellular protein degraders to target and eliminate disease-causing proteins currently in circulation. The enterprise engineers ASGPR Targeting Chimeras, or ATACs, which are specialized molecules designed to harness the body's natural processes to shuttle extracellular proteins to the endolysosome for degradation. To date, the biotechnology firm has raised $75 million in total seed financing to advance its preclinical research and development pipeline of novel therapeutics. This capital was secured from a syndicate of institutional investors that includes RA Capital Management, Sanofi Ventures, Medical Excellence Capital, and Astellas Venture Management. The organization recently presented preclinical in vivo proof-of-concept data demonstrating the efficacy of its degrader platform for treating diseases driven by extracellular proteins. Avilar Therapeutics was founded in 2019 by Milind Deshpande and founding investor RA Capital Management.
Avilar Therapeutics has raised $75.0M across 2 funding rounds.
Avilar Therapeutics has raised $75.0M in total across 2 funding rounds.
Avilar Therapeutics has raised $75.0M across 2 funding rounds. Most recently, it raised $15.0M Seed in February 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Feb 1, 2023 | $15M Seed | — | Polaris Partners | Announced |
| Nov 1, 2021 | $60M Seed | Joshua Resnick | Collide Capital, Gutter Capital, Listen, Sheila Lirio Marcelo, Turing Capital, Charles Huang | Announced |
Avilar Therapeutics has raised $75.0M in total across 2 funding rounds.
Avilar Therapeutics's investors include Polaris Partners, Joshua Resnick, Collide Capital, Gutter Capital, Listen, Sheila Lirio Marcelo, Turing Capital, Charles Huang.
Avilar Therapeutics is a biopharmaceutical company developing ATACs (ASGPR Targeting Chimeras), a novel class of extracellular protein degraders that shuttle disease-causing proteins from circulation to the endolysosome for degradation.[1][3][4] Founded in 2019 and based in Waltham, Massachusetts, the company targets high-value indications in women's health, autoimmune/rare neurology, and cardiometabolic disorders with both oral and injectable therapies, addressing proteins outside the cell that traditional degradation methods overlook.[1][2][3] It has raised $75M in funding, presented preclinical data at key summits, and secured U.S. Patent 11,819,551 for broad ATAC protection, signaling strong early momentum in targeted protein degradation.[2]
Avilar Therapeutics was founded in 2019 in Waltham, MA, as a biotech focused on expanding targeted protein degradation beyond intracellular targets to the extracellular proteome.[2][3] While specific founders are not detailed in available sources, the leadership includes a Chief Executive Officer & President, Chief Scientific Officer, and Senior Vice President/Chief Development Officer, driving its platform build.[2] The idea emerged from recognizing that nearly 40% of human proteins are extracellular or membrane-bound and implicated in diseases, yet undruggable by prior intracellular-focused degraders like PROTACs; Avilar pioneered ATACs to harness the liver's natural ASGPR-mediated endolysosomal degradation process.[3][4] Early traction includes a $75M funding round, preclinical pipeline advancements (e.g., IgG degraders for autoimmune diseases and AVL-181 for hepatitis C), patent issuance in 2023, and data presentations at the Targeted Protein Degradation Summit.[2][5]
Avilar rides the targeted protein degradation wave, shifting from intracellular PROTACs to extracellular targets, unlocking ~40% more of the proteome for diseases like autoimmune disorders and cardiometabolic conditions where secretion or circulation hinders traditional inhibition.[3][4] Timing aligns with surging investor interest—evidenced by $75M funding—and advances in endogenous degradation machinery, amid a biotech boom in precision modalities post-2020.[2] Market forces favoring Avilar include rising demand for first-in-class therapies in immunology and metabolism, plus patent protections amid competition from intracellular-focused players. It influences the ecosystem by validating extracellular degradation, potentially inspiring platform expansions and partnerships in the $100B+ protein degradation market.[2][3]
Avilar's ATAC platform positions it for pipeline milestones, including advancing preclinical assets like IgG degraders and AVL-181 into IND-enabling studies or Phase 1 trials, with oral formulations accelerating adoption.[1][5] Trends like AI-driven protein design and combo therapies with PROTACs will shape its path, amplifying extracellular focus amid ~3,000+ undruggable targets. Influence may evolve through big pharma deals or IPO as data readouts validate efficacy in hard-to-treat areas, cementing Avilar as a degradation pioneer—transforming a biotech boundary into standard care.[2][4]